MillerKM, FosterNC, BeckRW, et al.: Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care, 2015; 38:971–978.
2.
McKnightJA, WildSH, LambMJ, et al.: Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med, 2015; 32:1036–1050.
3.
WeinstockRS, Schutz-FuhrmannI, ConnorCG, et al.: Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. Diabetes Res Clin Pract, 2016; 122:28–37.
4.
CryerPE: Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med, 2013; 369:362–372.
5.
KitabchiAE, UmpierrezGE, MilesJM, FisherJN: Hyperglycemic crises in adult patients with diabetes. Diabetes Care, 2009; 32:1335–1343.
6.
RealsenJ, GoettleH, ChaseHP: Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. Diabetes Technol Ther, 2012; 14:1149–1154.
7.
Centers for Disease Control and Prevention: National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017.
8.
BodeBW, GargSK: The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract, 2016; 22:220–230.
9.
GargSK, MoserEG, BodeBW, et al.: Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract, 2013; 19:19–28.
10.
EllisSL, MoserEG, Snell-BergeonJK, RodionovaAS, HazenfieldRM, GargSK: Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med, 2011; 28:1176–1181.
11.
MathieuC, ZinmanB, HemmingssonJU, et al.: Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 2016; 39:1702–1710.
12.
PetrieJR, ChaturvediN, FordI, et al.: Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol, 2017.
13.
PieberTR, FamullaS, EilbrachtJ, et al.: Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab, 2015; 17:928–935.
14.
HenryRR, RosenstockJ, EdelmanS, et al.: Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care, 2015; 38:412–419.
15.
HenryRR, ThakkarP, TongC, PolidoriD, AlbaM: Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care, 2015; 38:2258–2265.
16.
GargSK, HenryRR, BanksP, et al.: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med, 2017; doi: 10.1056/NEJMoa1708337.
17.
HandelsmanY, HenryRR, BloomgardenZT, et al.: American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract, 2016; 22:753–762.
18.
EronduN, DesaiM, WaysK, MeiningerG: Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care, 2015; 38:1680–1686.
19.
PetersAL, BuschurEO, BuseJB, CohanP, DinerJC, HirschIB: Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care, 2015; 38:1687–1693.
20.
FralickM, SchneeweissS, PatornoE: Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med, 2017; 376:2300–2302.
21.
FadiniGP, BonoraBM, AvogaroA: SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia, 2017; 60:1385–1389.
22.
LapuertaP, ZambrowiczB, StrumphP, SandsA: Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diabetes and Vascular Disease Research, 2015; 12:101–110.
23.
ZambrowiczB, OgbaaI, FrazierK, et al.: Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther, 2013; 35:1162–1173.e8.
24.
DobbinsRL, GreenwayFL, ChenL, et al.: Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol, 2015; 308:G946–954.
25.
TaylorSI, BlauJE, RotherKI: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab, 2015; 100:2849–2852.
